trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['breast', 't-dxd', 'destiny,breast,2', 'destiny,breast,4', 'increase,(-increased)']
encouraging destiny-breast04 pros from #esmo22: fatigue scores remained stable over time in both treatment arms; an increase in nausea and vomiting was only clinically relevant in early cycles in the t-dxd arm with scores decreasing and remaining stable from cycles 7-27 